← Signals · Healthcare · TSX
$FRX
Fennec Pharmaceuticals Inc.
Signal as of August 17, 2026  ·  90-day rolling window  ·  Biotechnology & Life Sciences
Confluence Score
40
out of 100  ·  Full breakdown →
Score delayed 7 days on Free  ·  See today's score — Analyst →
Signals scoring 40–59 have historically hit 41% of the time (avg +7.1% over 90 days, 4424 backtested signals). Methodology →
🔒 Risk monitoring — insider-selling & reversal warnings (Analyst)
Confluence Score
40
Insider Activity (90d)
10
5 buyers  ·  —  ·  open-market only
Current Price
$15.49
CAD  ·  5-min cache
Market Cap
$543M
CAD  ·  TMX
Lobbying & Contracts
None
0 regs  ·  0 contracts
Healthcare on Form55: 43% hit rate · -5.4% alpha vs XIU.TO · 21 closed signals Track Record →
Signal Analyst
The Confluence Score and insider trade feed above are free. Signal Analyst adds the full component breakdown, lobbying registrations, and contract wins — plus alerts when this company's signal moves, so you don't have to keep checking back.
Monitor — CAD $29/mo
Price Chart
12 months daily  ·  TSX:FRX
Insider Transactions
90-day window  ·  14 filings
Date Insider Role Nature Dir. Shares Buy Price Return Value
Aug 03, 2026 Andrade, Robert Christopher Open Market Buy 1,703
Aug 03, 2026 Sayad, Pierre Open Market Buy 168
Aug 03, 2026 Hackman, Jeffrey Open Market Buy 1,159
Aug 03, 2026 Cioffi, Christiana Open Market Buy 156
Aug 03, 2026 Evans, Terry Open Market Buy 168
Jul 01, 2026 Evans, Terry Open Market Buy 168
Jul 01, 2026 Sayad, Pierre Open Market Buy 168
Jul 01, 2026 Andrade, Robert Christopher Open Market Buy 1,703
Jul 01, 2026 Hackman, Jeffrey Open Market Buy 1,159
Jul 01, 2026 Cioffi, Christiana Open Market Buy 156
Jun 10, 2026 Islam, Khalid Comp. Grant Buy 25,000 $8.70 +78.0%  · 75d $218K
Jun 10, 2026 Rallis, Chris Anigeron Comp. Grant Buy 20,000 $8.70 +78.0%  · 75d $174K
Jun 10, 2026 Brughera, Marco Comp. Grant Buy 20,000 $8.70 +78.0%  · 75d $174K
Jun 10, 2026 Jodi, Cook Comp. Grant Buy 20,000 $8.70 +78.0%  · 75d $174K
Score uses open-market buys only  ·  10 open-market  ·  4 plan / compensation shown but not scored  ·  Return is unrealized, to today's price; a “· Nd” mark means the 90-day window is still open (N of 90 days) — too early to judge.
Score Breakdown
Signal Analyst  ·  $29/mo
Component Points Max Detail Weight
Conviction (unique buyers)  ✓ FREE PREVIEW 20 30 5 unique buyers
Buy/sell ratio 20 100% buys (10B / 0S)
Dollar value 25 No open-market buys
Lobbying activity 15 None
Contract wins 10 None
Insider track record 10 No track record data
Private placements 8 None
Confluence bonus 10 None
Cluster timing (velocity) 10 No coordinated buying cluster detected
Buy/sell reversal pattern 8 No buy/sell reversal pattern
Total 40 100
Unlock Component Detail — CAD $29/mo
Buying Insiders
Open-market · 90 days · 5 unique buyers
Insider Credibility Hit Rate Avg 90d Return Trades (eval'd) Buy Value (90d) Last Buy
Evans, Terry Aug 03, 2026
Sayad, Pierre Aug 03, 2026
Andrade, Robert Christopher Aug 03, 2026
Hackman, Jeffrey Aug 03, 2026
Cioffi, Christiana Aug 03, 2026
Credibility score: historical hit rate × avg 90d return × sample size. View full insider leaderboard →
Lobbying Registrations
OCL active  ·  none found
No active OCL lobbying registrations in the last 90 days. Analyst plan →
Government Contract Wins
90-day window  ·  none found
No government contract wins in the last 90 days. Analyst plan →
Private Placements
12 months  ·  Signal Analyst  ·  $29/mo
Private placement history, deal size, and lock-up expiry tracking. Analyst plan →
Indigenous Consultation
no records on file

No Indigenous consultation records on file for FRX.

SEDAR+ Filings
official filing registry
Form55 monitors SEDAR+ filing alerts and newswire announcements for Technical Reports and material changes. Search SEDAR+ →
Short Interest
CIRO  ·  Aug 15, 2026
Shares short
24,705
Net change
+83 (+0.3%)
History
Aug 15: 24,705
Jul 31: 24,622
Jul 15: 24,762
Jun 30: 24,671
Jun 15: 23,408
May 31: 24,099
Aggregate short position from CIRO's Consolidated Short Position Report (published twice monthly).
Form55 provides data and analysis for informational purposes only. Nothing on this site constitutes investment advice or a recommendation to buy or sell any security. Past performance is not indicative of future results.